Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CHRNA7 | P36544 | 3/20 | 0.61 |
| ▸ | MEN1 | O00255 | 1/20 | 0.59 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.59 |
| ▸ | GAA | P10253 | 1/20 | 0.55 |
| ▸ | CHRM3 | P20309 | 2/20 | 0.55 |
| ▸ | HTR3E | A5X5Y0 | 1/20 | 0.54 |
| ▸ | HTR3B | O95264 | 1/20 | 0.54 |
| ▸ | HTR3A | P46098 | 1/20 | 0.54 |
| ▸ | HTR3D | Q70Z44 | 1/20 | 0.54 |
| ▸ | HTR3C | Q8WXA8 | 1/20 | 0.54 |
| ▸ | APOBEC3A | P31941 | 1/20 | 0.53 |
| ▸ | APOBEC3G | Q9HC16 | 1/20 | 0.53 |
| ▸ | HRH1 | P35367 | 2/20 | 0.51 |
| ▸ | SCN1A | P35498 | 1/20 | 0.51 |
| ▸ | SCN2A | Q99250 | 1/20 | 0.51 |
| ▸ | SCN3A | Q9NY46 | 1/20 | 0.51 |
| ▸ | CARM1 | Q86X55 | 1/20 | 0.50 |
| ▸ | PRMT6 | Q96LA8 | 1/20 | 0.50 |
| ▸ | POLB | P06746 | 1/20 | 0.48 |
| ▸ | MAPT | P10636 | 1/20 | 0.48 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Hydrochloric Acid SCHEMBL9312509 | 0.98 | MEN1 (0.62) | CHRNA7MEN1KMT2AGAACHRM3 | |
| Methylene Chloride SCHEMBL29003840 | 0.94 | CHRNA7 (0.55) | CHRNA7MEN1KMT2AGAACHRM3 | |
| SCHEMBL29068614 | 0.91 | CHRNA7 (0.52) | CHRNA7MEN1KMT2AGAACHRM3 | |
| SCHEMBL14390376 | 0.90 | CHRNA7 (0.58) | CHRNA7MEN1KMT2AGAACHRM3 | |
| SCHEMBL760593 | 0.90 | CHRNA7 (0.58) | CHRNA7MEN1KMT2AGAACHRM3 | |
| SCHEMBL760594 | 0.90 | CHRNA7 (0.58) | CHRNA7MEN1KMT2AGAACHRM3 | |
| Hydrochloric Acid SCHEMBL1723210 | 0.88 | CHRNA7 (0.56) | CHRNA7MEN1KMT2AGAACHRM3 | |
| Hydrochloric Acid SCHEMBL1723211 | 0.88 | CHRNA7 (0.56) | CHRNA7MEN1KMT2AGAACHRM3 | |
| SCHEMBL1786140 | 0.87 | MEN1 (0.69) | CHRNA7MEN1KMT2AGAAHTR3E | |
| SCHEMBL4453290 | 0.87 | MEN1 (0.69) | CHRNA7MEN1KMT2AGAAHTR3E |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 99 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20260022096-A1 | NOVEL SULFONAMIDES AND THEIR USE AS NEUROPROTECTIVE AND/OR NEURORESTORATIVE AGENTS | GENECODE (EE) | 2026-01-22 | — | — | US | disclosed |
| WO-2024125346-A1 | PREPARATION OF DEUTERATED 4-PHENYLPIPERIDINE-4-OL COMPOUND AND USE THEREOF | 南昌双天使生物科技开发有限公司 | 2024-06-20 | — | — | WO | disclosed |
| CN-117447388-B | Preparation and application of deuterated 4-phenylpiperidine-4-alcohol compound | 南昌双天使生物科技开发有限公司 | 2024-05-10 | — | — | CN | disclosed |
| CN-117447385-B | Preparation and application of deuterated 3-aminomethyl-4-phenylpiperidin-4-ol compound | 南昌双天使生物科技开发有限公司 | 2024-05-10 | — | — | CN | disclosed |
| CN-117447385-A | Preparation and application of deuterated 3-aminomethyl-4-phenylpiperidin-4-ol compound | 南昌双天使生物科技开发有限公司 | 2024-01-26 | — | — | CN | disclosed |
| CN-117447388-A | Preparation and application of deuterated 4-phenylpiperidine-4-alcohol compound | 南昌双天使生物科技开发有限公司 | 2024-01-26 | — | — | CN | disclosed |
| EP-3567041-B1 | SUBSTITUTED FUSED HETEROARYL COMPOUND SERVING AS A KINASE INHIBITOR, AND APPLICATIONS THEREOF | IMPACT THERAPEUTICS SHANGHAI INC (CN) | 2023-12-27 | — | — | EP | disclosed |
| US-20230218597-A1 | SUBSTITUTED PYRIDINES AND METHODS OF USE | THERAVANCE BIOPHARMA R&D IP LLC (US) | 2023-07-13 | — | — | US | disclosed |
| CN-108456204-B | Benzothiazine derivative, and preparation method and application thereof | 四川大学 | 2023-05-26 | — | — | CN | disclosed |
| EP-3567041-A9 | SUBSTITUTED FUSED HETEROARYL COMPOUND SERVING AS A KINASE INHIBITOR, AND APPLICATIONS THEREOF | Impact Therapeutics (Shanghai), Inc (CN) | 2022-04-20 | — | — | EP | disclosed |
| US-5661148-A | ANTIHYPOXIC AGENT FOR RESPIRATORY SYSTEM DISORDER | TEIJIN LIMITED (JP) | 1997-08-26 | — | — | US | disclosed |
| EP-0514540-B1 | PYRROLO 2,3-d]PYRIMIDINE DERIVATIVE, PROCESS FOR PREPARING THE SAME, AND PHARMACEUTICAL PREPARATION COMPRISING THE DERIVATIVE AS ACTIVE INGREDIENT | TEIJIN LTD (JP) | 1996-07-17 | — | — | EP | disclosed |
| CN-1075960-A | Amino benzoyl guanidine, its preparation method that replaces is as the purposes and the medicament that contains it of medicine | HOECHST AG (DE) | 1993-09-08 | — | — | CN | disclosed |
| EP-0514540-A1 | PYRROLO 2,3-d]PYRIMIDINE DERIVATIVE, PROCESS FOR PREPARING THE SAME, AND PHARMACEUTICAL PREPARATION COMPRISING THE DERIVATIVE AS ACTIVE INGREDIENT | TEIJIN LIMITED (JP) | 1992-11-25 | — | — | EP | disclosed |
| EP-0157472-B1 | PROCESS FOR POLYMERIZATION OF OLEFINS | TOA NENRYO KOGYO KABUSHIKI KAISHA (JP) | 1990-03-07 | — | — | EP | disclosed |
| EP-0155847-B1 | A STABILIZER FOR SYNTHETIC RESINS AND RESINS STABILIZED THEREBY | SUMITOMO CHEMICAL COMPANY, LIMITED (JP) | 1989-11-08 | — | — | EP | disclosed |
| EP-0171139-B1 | HIGH POLYMER STABILIZER CONTAINING A PHENOLIC COMPOUND, AND HIGH POLYMERS STABILIZED THEREBY | SUMITOMO CHEMICAL COMPANY, LIMITED (JP) | 1989-07-26 | — | — | EP | disclosed |
| EP-0156512-B1 | PROCESS FOR PREPARING CATALYST COMPONENT FOR POLYMERIZATION OF OLEFINS | TOA NENRYO KOGYO KABUSHIKI KAISHA (JP) | 1989-06-14 | — | — | EP | disclosed |
| EP-0106618-B1 | STABILIZERS FOR SYNTHETIC RESINS | SUMITOMO CHEMICAL COMPANY, LIMITED (JP) | 1988-02-10 | — | — | EP | disclosed |
| EP-0102193-B1 | STABILIZERS FOR SYNTHETIC RESINS | SUMITOMO CHEMICAL COMPANY, LIMITED (JP) | 1986-10-29 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20260022096-A1 | NOVEL SULFONAMIDES AND THEIR USE AS NEUROPROTECTIVE AND/OR NEURORESTORATIVE AGENTS | CNR1, CDR2, SMN1; SMN2 | CHRNA7 243/4885MEN1 3316/4885KMT2A 4062/4885 |
| US-20230218597-A1 | SUBSTITUTED PYRIDINES AND METHODS OF USE | ALK, ACVR1, ACVR2A | CHRNA7 560/4885MEN1 3345/4885KMT2A 3260/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.